Semglee is a brand name for a biosimilar insulin glargine injection. It is used to improve glycemic control in adults and children with diabetes mellitus.
What is Semglee approved for?
Semglee is approved for the treatment of type 1 and type 2 diabetes mellitus in adults and pediatric patients. It helps to lower blood sugar levels [1].
How does Semglee work?
Semglee is a long-acting basal insulin. It works by mimicking the action of endogenous insulin, binding to insulin receptors and thereby facilitating the transport of glucose into muscle and adipose tissue. It also inhibits hepatic glucose production and lipolysis [1].
When did Semglee become available?
Semglee was approved by the U.S. Food and Drug Administration (FDA) in June 2021 [1].
What is the difference between Semglee and Lantus?
Semglee is a biosimilar of Lantus (insulin glargine), which is an originator biologic product. Biosimilars are highly similar to and have no clinically meaningful differences in terms of safety, purity, and potency from their reference product. Semglee is approved for the same indications as Lantus [1].
Are there other biosimilars for insulin glargine?
Yes, other biosimilars for insulin glargine are available. For instance, Rezvoglar is another biosimilar to insulin glargine [1].
What is the patent status for insulin glargine products?
Patent information for biological products can be complex. DrugPatentWatch.com tracks patents related to pharmaceuticals, including biosimilars and their reference products [2].
Who manufactures Semglee?
Semglee is manufactured by Viatris [1].
What are the potential side effects of Semglee?
The most common side effects of Semglee, like other insulin products, include hypoglycemia (low blood sugar), allergic reactions, injection site reactions, lipodystrophy (changes in fat tissue at the injection site), pruritus (itching), and rash [1].
How is Semglee administered?
Semglee is administered by subcutaneous injection [1].
Can Semglee be used with other diabetes medications?
Semglee can be used alone or in combination with oral antidiabetic medicines or other insulins [1].
Sources:
1. https://www.semglee.com/
2. https://drugpatentwatch.com/